Right temperature, right time, right now - UPS
The evolution of cold chain technology and its use by UPS Healthcare
Cold chain technology in the logistics world has been around for decades, transforming from simpler times of packing food in ice during transport, to today’s complex movement of life-saving vaccines at ultra-cold temperatures. Although advancements in technology have made it easier to ship temperature-controlled products around the world, the basic concept has stayed the same: keep goods at the right temperatures to ensure efficacy and safety for the end customer.
UPS Healthcare has leveraged cutting edge cold chain tools and technology since 2000, helping to keep healthcare packages at the right temperatures during transport. The company continued investments throughout the years, moving toward the recent global delivery of COVID-19 vaccines with near-perfect service. Its continued success is creating long-term value for the future delivery of new drugs, especially biologics and temperature-controlled therapies, which make up more than half of all new drugs in the pipeline.
The evolution of cold chain technology and its use by UPS Healthcare
Cold chain technology in the logistics world has been around for decades, transforming from simpler times of packing food in ice during transport, to today’s complex movement of life-saving vaccines at ultra-cold temperatures. Although advancements in technology have made it easier to ship temperature-controlled products around the world, the basic concept has stayed the same: keep goods at the right temperatures to ensure efficacy and safety for the end customer.
UPS Healthcare has leveraged cutting edge cold chain tools and technology since 2000, helping to keep healthcare packages at the right temperatures during transport. The company continued investments throughout the years, moving toward the recent global delivery of COVID-19 vaccines with near-perfect service. Its continued success is creating long-term value for the future delivery of new drugs, especially biologics and temperature-controlled therapies, which make up more than half of all new drugs in the pipeline.
